

MDM2 (Clone: D7) Mouse Monoclonal Antibody

PRODUCT INFORMATION:	PERFORMANCE CHARACTERISTICS:
PM263 6ml Ready to use	Localization: Nucleus
PM263 3ml Ready to use	Retrieval Buffer: Tris-EDTA, pH 9.0
CM263 1ml Concentrated	Incubation: 30-60 minutes
CM263 0.5ml Concentrated	Positive control: Breast Ca, Brain
CM263 0.1ml Concentrated	
HAM263 6ml Ready to use	
HAM263 3ml Ready to use	

INTENDED USE

For *in vitro* diagnostic use only

This antibody is intended for use in qualitatively identify MDM2 antigen by light microscopy in formalin fixed, paraffin embedded (FFPE) tissue sections using immunohistochemical (IHC) detection methodology. Interpretation of any positive or negative staining must be complemented with the evaluation of proper known controls (Positive and Negative) and must be made within the context of the patient's clinical history and other diagnostic tests. A qualified and trained pathologist must perform evaluation of the test. This antibody is intended to be used after the primary diagnosis of tumor has been made by conventional histopathology using nonimmunologic histochemical stains.

SUMMARY AND EXPLANATION

p53 is the most commonly mutated gene in human cancer identified to date. Expression of p53 leads to inhibition of cell growth by preventing progression of cells from G1 to S phase of the cell cycle. Most importantly, p53 functions to cause arrest of cells in the G1 phase of the cell cycle following any exposure of cells to DNA-damaging agents. The MDM2 (murine double minute 2) protein was initially identified as an oncogene in a murine transformation system. MDM2 functions to bind p53 and block p53-mediated transactivation of co-transfected reporter constructs. The MDM2 gene is amplified in a high percentage of human sarcomas that retain wildtype p53 and tumor cells that over express MDM2 can tolerate high levels of p53 expression. These findings argue that MDM2 over expression represents at least one mechanism by which p53 function can be abrogated during tumorigenesis.

PRINCIPLE OF THE PROCEDURE

The identification of the antigen on the FFPE tissues is carried out using the above stated antibody. The antigen and antibody complex is visualized using an enzyme coupled (HRP/AP) secondary antibody with specific binding to the primary antibody, this complex is visualized by the enzymatic activation of the chromogen resulting to a visible reaction production of the antigenic site. Each and every step involves precise time and optimal temperature and the results are interpreted using a light microscope by a qualified and trained pathologist.

REAGENT PROVIDED

Concentrated format: Antibody to MDM2 is affinity purified and diluted in antibody diluent with 1% bovine serum albumin (BSA) and 0.05% of sodium azide (NaN₃).

Recommended dilutions: 1:50 – 1:100

The antibody dilution and protocol may vary depending on the specimen preparation and specific application. Optimal conditions should be determined by individual laboratory.

Pre-diluted format: PathnSitu's ready to use antibodies are pre-titrated to optimal staining conditions. Further dilution will affect the efficacy of the antibody and may yield to sub-optimal staining.

Immunogen: MDM2 (D-7) is a mouse monoclonal antibody raised against amino acids 100-320 of MDM2 of human origin.

Host, Isotype: Mouse, IgG 2b kappa.

STORAGE AND HANDLING

Storage Recommendations: Store at 2-8°C. When stored at the appropriate conditions, the antibody is stable until expiry. Do not use the antibody after expiration date provided on the vial in any condition.

To ensure proper reagent delivery and stability, replace the dispenser cap after every use and immediately place the vial into the refrigerated conditions in an upright position. The contents of the vial should be used within 9 months from the

opening of the vial.

SPECIMEN PREPARATION

Staining Recommendations:

Routinely processed, FFPE tissues are suitable for use with this primary antibody, when used PathnSitu's Poly Excel HRP/DAB detection system. The recommended tissue fixative is 10% neutral buffered formalin. Variable results may occur as a result of prolonged fixation or special processes such as decalcification. Thickness of the sections should be 2-5µm. Slides should be stained once the sections are made as antigenicity of the cut sections may diminish over a period of time. It is recommended to stain known positive and negative controls simultaneously with unknown specimens.

PRECAUTIONS

1. This product should be used by qualified and trained professional users only
2. The product contains < 0.1% of sodium azide as preservative and is not classified hazardous, refer MSDS for further details
3. As with any product derived from biological sources, proper handling procedures should be used
4. Do not use reagents after expiration date
5. Use protective clothing and gloves, while handling reagents
6. All hazardous materials should be disposed according to local state and federal regulations
7. Avoid microbial contamination of reagents as it may lead to incorrect results

STAINING PROCEDURE

Antigen Retrieval Solution: Use Tris-EDTA Buffer (Cat#PS009) as antigen retrieval solution.

Heat Retrieval Method: Retrieve sections under steam pressure for 15 minutes using PathnSitu's MERS (Multi Epitope Retrieval System) for optimal retrieval of the epitopes, allow solution to cool at the room temperature, transfer the tissue sections/slides to the distilled water prior to the primary antibody application.

Primary Antibody: Cover the tissue sections with primary antibody and incubate for 30-60 min at room temperature when used PathnSitu's PolyExcel Detection System.

Detection System: Refer to PathnSitu's PolyExcel HRP/ DAB detection system protocol for optimal staining results.

QUALITY CONTROL

The recommended positive tissue control for MDM2 is Brain and Breast Carcinoma. A positive and negative tissue control must be run with every staining procedure performed for monitoring the correct performance of processed tissue and test reagents. A negative tissue controls provide an indication of non-specific background staining. If the results are not expected in positive and negative controls the test must be considered invalid and entire procedure must be cross verified. Individual laboratory must establish their own quality control to validate the process and antibody when opened a vial.

INTERPRETATION OF RESULTS

MDM2 stains the Nucleus. A qualified experienced/trained pathologist must interpret the results in the patient's sample along with the positive and negative controls.

PERFORMANCE CHARACTERISTICS

PathnSitu products will undergo a thorough quality control check before it is released to the market. The antibody showed consistent specific and sensitive staining on the multiple positive tissue controls tested, by inter run, intra run and lot based studies. The antibody is stable for the expiry mentioned on the labels which is determined by real time or accelerated methods.

TROUBLESHOOTING

1. Follow the antibody specific protocol recommendations according to data sheet provided
2. Tissue staining is dependent on the handling and processing of the tissue prior to staining. Improper fixation, tissue processing, antibody freezing and thawing, washing, drying, heating, sectioning or contamination with other tissues or fluids may produce artifacts, antibody trapping or inaccurate results
3. Do not allow the section to dry out during the entire IHC process
4. Excessive or incomplete counterstaining may compromise the interpretation

of the results

- If unusual results occur, contact PathnSitu's Technical Support at +91-40-2701 5544 or E-mail: techsupport@pathnsitu.com

LIMITATIONS AND WARRANTY

Authorized and skilled/trained personnel only may use the product. The clinical interpretation of any test results should be evaluated within the context of the patient's medical history and other diagnostic test results. A qualified trained pathologist must perform the evaluation of the test results. There are no warranties, expressed or implied, which extend beyond the description. PathnSitu is not liable for property damage, personal injury, time or effort on economic loss caused by this product.

BIBLIOGRAPHY

- White, D.E., et al. 2006. Mouse double minute 2 associates with chromatin in the presence of p53 and is released to facilitate activation of transcription. *Cancer Res.* 66: 3463-3470.
- Ding, Y., et al. 2006. Interferon-inducible protein IFIX α 1 functions as a negative regulator of HDM2. *Mol. Cell. Biol.* 26: 1979-1996.
- Sayan, B.S., et al. 2007. Cleavage of the transactivation-inhibitory domain of p63 by caspases enhances apoptosis. *Proc. Natl. Acad. Sci. USA* 104: 10871-10876.
- Iizuka, M., et al. 2008. HBO1 Links p53-dependent stress signaling to DNA replication licensing. *Mol. Cell. Biol.* 28: 140-153.
- Sarafraz-Yazdi, E., et al. 2010. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. *Proc. Natl. Acad. Sci. USA* 107: 1918-1923.
- Bom, A.P., et al. 2010. The p53 core domain is a molten globule at low pH: functional implications of a partially unfolded structure. *J. Biol. Chem.* 285: 2857-2866.
- Ferraz da Costa, D.C., et al. 2012. Transient transfection of a wild-type p53 gene triggers resveratrol-induced apoptosis in cancer cells. *PLoS ONE* 7: e48746.


EXPLANATION OF SYMBOLS

LOT- Lot number / Batch number



- Expiry

IVD *In vitro* diagnostic use



Storage limitation